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Abstract
A large body of evidence suggests that, besides their cholesterol-lowering effect, statins exert anti-inflammatory action.
Consequently, statins may have therapeutic potential in immune-mediated disorders such as multiple sclerosis. Our
objectives were to determine safety, tolerability and efficacy of low-dose atorvastatin plus high-dose interferon beta-1a in
multiple sclerosis patients responding poorly to interferon beta-1a alone. Relapsing–remitting multiple sclerosis patients,
aged 18–50 years, with contrast-enhanced lesions or relapses while on therapy with interferon beta-1a 44 mg (three
times weekly) for 12 months, were randomized to combination therapy (interferon + atorvastatin 20mg per day;
group A) or interferon alone (group B) for 24 months. Patients underwent blood analysis and clinical assessment
with the Expanded Disability Status Scale every 3 months, and brain gadolinium-enhanced magnetic resonance imaging
at screening, and 12 and 24 months thereafter. Primary outcome measure was contrast-enhanced lesion number.
Secondary outcome measures were number of relapses, EDSS variation and safety laboratory data. Forty-five patients
were randomized to group A (n¼ 21) or B (n¼ 24). At 24 months, group A had significantly fewer contrast-enhanced
lesions versus baseline (p¼ 0.007) and significantly fewer relapses versus the two pre-randomization years (p< 0.001).
At survival analysis, the risk for a 1-point EDSS increase was slightly higher in group B than in group A (p¼ 0.053).
Low-dose atorvastatin may be beneficial, as add-on therapy, in poor responders to high-dose interferon beta-1a alone.
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Introduction
Multiple sclerosis (MS) is the most common inﬂamma-
tory disease of the central nervous system, and one of
the leading causes of neurological disability among
young adults. Indeed, it aﬀects approximately 1 million
people world-wide,1 with a median onset age of 28
years.2 The drugs available for MS are immunomodu-
lators, in particular compounds of the beta interferon
(IFN) family. However, they are associated with incom-
plete eﬃcacy and several adverse eﬀects. Therefore,
new, more eﬃcacious and more easily administered
drugs, or combination therapies, are eagerly awaited.
Atorvastatin, an HMG-CoA reductase inhibitor,
widely used to reduce serum cholesterol levels, was
found to decrease both the severity and number of
relapses in an animal model of MS, that is, murine
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experimental autoimmune encephalomyelitis.3,4 This
ﬁnding prompted several trials with statins alone or
as add-on therapy to IFN beta in relapsing–remitting
(RR) MS patients. However, the trials produced con-
trasting results. Simvastatin, another HMG-CoA
reductase inhibitor, reduced the numbers and size of
contrast enhanced lesions (CELs) in brain magnetic res-
onance imaging (MRI) studies of RR-MS patients in an
open label trial.5 Atorvastatin, as add-on therapy to
IFN beta-1a 44 mg subcutaneously (sc) three times
weekly, resulted in increased disease activity in a
small cohort of RR-MS patients in a double-blind
placebo-controlled trial lasting 6 months.6 On the
other hand, Paul and colleagues7 reported a beneﬁcial
eﬀect of high-dose atorvastatin, alone or in combina-
tion with IFN, on the development of new CELs at
MRI, over a 9-month treatment period, with a trend
towards signiﬁcance in the combination treatment
group. Lastly, a retrospective study by Rudick et al.8
comparing patients on IFN beta-l a 30 mg intramuscular
(i.m.) therapy alone (n¼ 542) and patients on the same
IFN schedule but taking various statins for hyperlipi-
daemia (n¼ 40), at diﬀerent dosages and for diﬀerent
lengths of time, showed no clinical or MRI diﬀerences.
In addition, statins did not aﬀect either the ex vivo or
in vitro induction of IFN-stimulated genes.8
The aim of this study was to investigate the safety
and eﬃcacy of low-dose atorvastatin as add-on therapy
in a cohort of RR-MS patients responding poorly to
IFN beta-1a alone, in long-term follow-up.
Patients and methods
From April 2005 to April 2006, 93 consecutive outpa-
tients of the MS Center of the Federico II University
Hospital (Naples, Italy), with clinically deﬁnite RR–
MS according to the McDonald criteria,9 aged 18–50
years, were treated with IFN beta-1a 44 mg three times
weekly. Patients were monitored for 12 months (run-in
period); visits were scheduled every 3 months and
included Expanded Disability Status Scale (EDSS)
assessment, and unscheduled visits to verify probable
relapses each time the patients contacted the centre for
any subjective symptom. Disease history, including
information about relapses that occurred during the
24 months before randomization, was collected. At
the end of the 12-month run-in period, a screening
visit with EDSS assessment and MRI was scheduled.
Patients with disease activity (at least one relapse or one
gadolinium-enhanced lesion at screening MRI) were
randomized to continue IFN in combination with
atorvastatin 20mg per day (group A) or IFN alone
(group B) for 24 months.
After randomization, EDSS and laboratory para-
meters were assessed at 1 month and every 3 months
for 24 months, and brain MRI was performed after
12 and 24 months. Both the examining neurologist (for
EDSS and relapse assessment) and the neuroradiologist
were blinded to treatment assignment. The primary out-
come was number of MRI CELs. Secondary outcomes
were the number of clinical relapses, EDSS score varia-
tion and safety laboratory parameters. During the study,
patients received no other immunomodulatory or immu-
nosuppressive therapy. In the case of a conﬁrmed
relapse, a 3-day cycle of methylprednisolone (totally
3 g intravenously (i.v.)) was prescribed.
Ethics committee approval was obtained, and each
patient gave their signed informed consent to participate
in the study. Atorvastatin was supplied by the manufac-
turer Pﬁzer (Pﬁzer Italia, Latina, Rome). Safety mea-
sures were as follows: patients underwent serum
chemistry and haemocromocytometric analyses that
included Aspartate Aminotransferase (AST), Alanine
Aminotransferase (ALT), kidney function tests, total
cholesterol, LDL cholesterol, HDL cholesterol, creatine
phospho-kinase (CPK), thyroid function tests and vital
signs. Blood testing was performed in the morning after
a 12-hour fast. Laboratory values 2.5-fold below or
above normal range were considered adverse events.
Statistical analysis
Continuous variables were compared by mixed-model
analysis of variance (ANOVA) with the F test.
Categorical variables were compared by the 2 test
with Fisher exact test, and, where appropriate, by
non-parametric multivariate analysis of variance
(MANOVA) for repeated measures (per-protocol ana-
lysis, performed only in patients who completed 24
months of treatment). For survival analyses, the time
in the cohort was deﬁned from study entry to the last
clinical observation and/or failure event. Failure event
was deﬁned as a 1-point EDSS increase sustained for at
least 3 months. We used the log-rank test to compare
the equality of survival functions. For all statistical
tests, a p-value< 0.05 was considered signiﬁcant. The
STATA 10 (StataCorp, College Station, TX, USA)
program was used for statistical analyses.
Results
At screening, 45 subjects had active disease (23 had
relapses and 22 had CELs while on IFN treatment)
and were enrolled and randomized to combination
therapy (n¼ 21; group A) or IFN alone (n¼ 24;
group B). At baseline, age, sex distribution, disease
duration, the total number of relapses (Table 1), the
number of relapses during the 24 months before ran-
domization, CEL number and EDSS score (Table 2)
were comparable in the two groups. The number of
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CELs at screening ranged from 0 to 5 in group A and
from 0 to 9 in group B. During follow-up, 2 patients
dropped out in group A: the ﬁrst at month 9 for depres-
sion and the second at month 18 for amenorrhoea and
increased spasticity. Five patients of group B dropped
out, 1 for pregnancy at month 12, 2 for clinical disease
activity at month 15 and month 18 respectively, 1 for
secondary progression and 1 for depression, both at
month 21. Thirty-eight patients (19 group A and 19
group B) completed the study.
Primary endpoint – number of contrast-enhanced
lesions. Treatment resulted in a decrease in the
number of CELs in both groups. The diﬀerence
between baseline and 24-month follow-up was signiﬁ-
cant in group A (p¼ 0.007) but not in group B
(p¼ 0.317) (Table 2 and Figure 1). The diﬀerence
between the two groups was not signiﬁcant (p¼ 0.10).
Secondary endpoints – number of relapses, EDSS
score variations and laboratory parameters. There
were 10 relapses in 8 group A patients (53%
relapse-free) and 30 relapses in 13 group B patients
(32% relapse-free). The mean relapse number during
the 24 months of follow-up was 0.5 0.7 in group A
versus 1.6 1.8 in group B (p¼ 0.03). There were fewer
relapses during the 24-month follow-up than during the
2 years before randomization in both groups; the dif-
ference was signiﬁcant in group A (p< 0.001) but not in
group B (p¼ 0.33) (Table 2; Figure 2), and there was a
signiﬁcant group eﬀect (p< 0.005).
A sustained increase of EDSS score of at least
1 point was observed in 4 patients of group B (17%),
2 of whom dropped out before study completion, and
in no patient of group A. ANOVA analysis with
repeated measures showed a signiﬁcant increase in
EDSS at 24 months in group B patients (p¼ 0.039)
but not in group A patients (p¼ 0.80) without a signif-
icant group eﬀect (p¼ 0.60) (Table 2). We used survival
analysis to determine the likelihood of experiencing a
1-point EDSS increase in the two groups. Group B
patients were at a greater risk for clinical worsening
than group A patients, but the diﬀerence was not
quite signiﬁcant (p¼ 0.053).
At baseline, serum levels of total, LDL and HDL
cholesterol and triglycerides did not diﬀer signiﬁcantly
between the two groups. In fact, total cholesterol
ranged between 2.5 and 6.8mmol/L in group A and
between 2.7 and 7.6mmol/L in group B (normal
laboratory range: 2.4–5.5mmol/L; desirable value:
<4.9mmol/L). LDL ranged between 1.1 and 5mmol/L
in group A and between 0.7 and 1.9 mmol/L in group B
(normal laboratory range:1.5–3.9mmol/L; desirable
value: <3.4 mmol/L). Serum total cholesterol
and LDL serum levels decreased signiﬁcantly in group
A from a mean of 4.2 1.1 mmol/L and
2.2 0.9mmol/L respectively, at baseline, to a mean
of 3.4 1mmol/L and 1.6 0.8mmol/L, at the 24-
month follow-up examination (p=0.03 and p<0.005,
respectively). The other laboratory parameters, even
CPK and liver enzymes, remained unchanged. No
muscle pain or cramps were reported in either group.
Table 2. Clinical and neuroradiologic characteristics of group A (interferon + atorvastatin) and group B (interferon) patients at
baseline and after 24 months of follow-up
Group A Group B
Treatment effect
at repeated
measures analysis
Baseline Follow-up p Baseline Follow-up p p
CELsa 1.3 1.5 0.11 0.45 p¼ 0.007 1.1 2.3 0.6 1.5 p¼ 0.32 p¼ 0.10
Relapsesa,b 2.6 1.1 0.5 0.7 p< 0.001 2.1 1.2 1.6 1.8 p¼ 0.33 p< 0.005
EDSSa 2.8 1.1 3.0 1.1 p¼ 0.80 3.0 1.1 3.4 1.1 p¼ 0.04 p¼ 0.60
aMean SD.
bNumber of relapses in the 2 years before randomization.
CELs, contrast-enhanced lesions; EDSS, Expanded Disability Status Scale.
Table 1. Clinical and demographic characteristics at baseline
of group A (interferon + atorvastatin) and group B (interferon)
Group A
atorvastatin +
interferon beta
alone
Group B
atorvastatin +
interferon beta
alone p
Number 21 24
Agea (years) 31.5 9 32.9 7 0.81
Female/male 14/7 15/9 0.77
Disease durationa
(months)
98.4 68.1 104.2 64.3 0.97
Total relapsesa 6.9 3.7 6.6 4.3 0.52
aMean SD.
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Discussion
Several studies suggest that, besides their cholesterol-
lowering eﬀect, statins exert anti-inﬂammatory action.
Therefore, these compounds may have therapeutic
potential in immune-mediated disorders such as MS.
Atorvastatin has been shown to modulate the clinical
course of experimental autoimmune encephalitis, which
is the best characterized animal (murine) disease model
of MS.3,4,10 Statins in combination with IFN beta exert
synergistic eﬀects in the suppression of T-cell prolifer-
ation.11 On the other hand, lowering of cholesterol
levels has been reported to have a detrimental eﬀect
in an animal model of the disease.12
Clinical trials have yielded contrasting results about
the eﬀect of statin/IFN combinations on RR-MS
patients.5–8 It is diﬃcult to compare the data from
these trials because of diﬀerences in the statins used, in
the dosage and in the kinds of patients enrolled. In par-
ticular, Birnbaum and colleagues6 reported that the
addition of atorvastatin, 40mg or 80mg daily, to IFN
beta-1a, 44 mg s.c. three times weekly, resulted in
increased disease activity (at MRI and/or clinically).
The authors suggested that this unexpected result was
because, at the dosage used, statins could have exerted
an antagonistic eﬀect on IFN activity. On the other
hand, no antagonistic eﬀects emerged from the interim
safety analysis of 47 patients in the SIMCOMBIN trial
treated with simvastatin 80mg or placebo in addition to
IFN beta-1a 30 mg i.m.13 Lastly, CEL number decreased
in active RR-MS patients on atorvastatin 80mg daily in
combination with IFN beta-1a in a 9-month trial.7
We studied low-dose atorvastatin, as add-on therapy
to IFN beta-1a, for the longest period reported so far, to
determine whether it might be beneﬁcial or detrimental,
in an RR-MS population who responded poorly to IFN
alone. Our results show that combination therapy was
safe and well tolerated. More interestingly, we observed
a signiﬁcant reduction of CEL number at MRI and of
relapses, with a stable EDSS score, only in the combina-
tion therapy group. Direct between-group comparison
showed that the decrease in relapses was signiﬁcantly
associated to a treatment eﬀect of statins, whereas
there was a trend towards a decrease in CEL number.
This discrepancy is probably due to the small sample
sizes but, in any event, these results argue against a pos-
sible detrimental eﬀect of the association, as also recently
suggested.6 Moreover, drop-outs because of disease
activity or progression occurred only in the IFN-alone
group. Regression to the mean, that is, a reduction of
CEL number and relapses, is a spontaneous phenome-
non in MS populations with active disease, irrespective
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Figure 1. Contrast-enhanced lesions (means standard error of the mean) at baseline, and at 12 and 24months of follow-up. Data are
plotted for the two treatment groups. Group A: combination therapy; group B: interferon alone therapy. *p¼ 0.007 versus baseline.
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Figure 2. Relapses in the 2 years before randomization and in
the 2 years of follow-up. Group A: combination therapy; group B:
interferon alone therapy. *p< 0.005 compared versus
pre-randomization.
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of therapy.14 However, since our two groups were highly
comparable at baseline, the diﬀerent outcome of therapy
observed at follow-up cannot be attributed solely to a
regression to the mean eﬀect.
In conclusion, our data suggest that a low dose of
atorvastatin, as add-on therapy to IFN, is safe and
might be beneﬁcial in a population of RR-MS patients
who respond poorly to IFN alone. Further studies,
with larger cohorts of patients and a longer follow-up,
are required to verify this aﬃrmation and to clarify the
eﬀects of statins in MS.
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